...
首页> 外文期刊>Journal of Clinical Oncology >Improving relative survival, but large remaining differences in survival for non-Hodgkin's lymphoma across Europe and the United States from 1990 to 2004.
【24h】

Improving relative survival, but large remaining differences in survival for non-Hodgkin's lymphoma across Europe and the United States from 1990 to 2004.

机译:1990年至2004年,在欧洲和美国,非霍奇金淋巴瘤的相对生存率有所提高,但生存率仍存在较大差异。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: Non-Hodgkin's lymphoma (NHL) is the most common hematologic malignant neoplasm in adults. Monitoring differential changes in population-based survival is across Europe and the United States (US) could point to progress attained and impact of application of novel treatments. PATIENTS AND METHODS: We examined trends in age-specific 5-year relative survival among patients with NHL age 15 years or older between 1990 and 1994 and 2000 and 2004, on the basis of follow-up data from 12 population-based cancer registries across Europe, using period analysis techniques and compared the results with similar trends of patients with NHL in the US, as recorded in the Surveillance, Epidemiology, and End Results database. RESULTS: By 2000 to 2004, overall 5-year relative survival of patients with NHL across Europe was between 37% and 62%, achieved by overall increases in 5-year relative survival ranging from 4% to 12% units between 1990 and 1994 and 2000 and 2004. Changes in age-specific survival ranged from -1% to 43% units during the same time interval. For patients with NHL older than age 55 years, relative survival in individual European registries for the whole period was between 8% and 36% units lower than in the US, theoretically representing a lag of 4 to 10 years of progress. CONCLUSION: Our analyses disclosed a strong and ongoing increase in long-term survival for patients with NHL in European populations. The geographic differences potentially indicate that further improvements could be possible, especially for patients age 55 years or older. The presumptive delay in improvement in survival among elderly patients with NHL in Europe remains to be clarified.
机译:目的:非霍奇金淋巴瘤(NHL)是成人中最常见的血液恶性肿瘤。在欧洲和美国(美国),监测以人口为基础的生存的差异性变化可能会指出取得的进展以及采用新疗法的影响。患者和方法:我们根据1990年至1994年以及2000年至2004年之间15岁或以上的NHL年龄患者的特定年龄5年相对生存趋势,根据12个基于人群的癌症登记机构的随访数据在欧洲,使用了时段分析技术,并将结果与​​美国NHL患者的类似趋势进行了比较,如监测,流行病学和最终结果数据库中记录的那样。结果:到2000年至2004年,欧洲所有NHL患者的5年总体相对生存率在37%至62%之间,这是通过1990年至1994年之间5年相对生存率总体提高(从4%至12%单位)实现的。 2000年和2004年。在同一时间间隔内,特定年龄段生存率的变化范围从-1%到43%。对于55岁以上的NHL患者,整个欧洲各个注册机构的相对生存期都比美国低了8%至36%,理论上来说这是4到10年的滞后。结论:我们的分析显示,欧洲人群中的NHL患者长期存活率持续强劲增长。地域差异可能表明可能会有进一步的改善,特别是对于55岁以上的患者。在欧洲,老年NHL患者生存改善的推测性延迟尚待阐明。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号